Entrada publishes corporate deck outlining DMD, DM1 pipeline catalysts and $5 billion US market opportunity

Entrada Therapeutics Inc

Entrada Therapeutics Inc

TRDA

0.00
  • Entrada outlined plans to expand to 5 clinical-stage programs across Duchenne muscular dystrophy and myotonic dystrophy type 1 by year-end 2026.
  • Company flagged 4 clinical data catalysts expected in 2026 across DMD and DM1 patients.
  • Lead DMD program ENTR-601-44 targets Cohort 1 data in Q2 2026.
  • Second dose-escalation cohort for ENTR-601-44 was cleared to start at 12 mg/kg, with data expected by year-end 2026.
  • Entrada reported cash runway into Q3 2027, with about $296 million cash as of year-end 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.